Skip to main content
. 2016 Jun 10;6(6):e434. doi: 10.1038/bcj.2016.41

Figure 4.

Figure 4

Ibrutinib does not induce LOH of the remaining wild-type Trp53 allele compared with vehicle treatment. (a) LOH at the Trp53 locus in B-cells from tumor burdened spleens and lymph nodes from vehicle- and ibrutinib-treated Eμ-TCL1;p53R172H/+ mice. (b) Percentage of LOH at the Trp53 locus in spleens and lymph nodes from tumor burdened Eμ-TCL1;p53R172H/+ mice treated with ibrutinib (n=29) or vehicle (n=37).